
Unicycive Therapeutics (UNCY) Stock Forecast & Price Target
Unicycive Therapeutics (UNCY) Analyst Ratings
Bulls say
Unicycive Therapeutics is expected to experience increased operating expenses and cash burn as it prepares for the commercial launch of its primary product candidate OLC, which has a PDUFA date of June 29, 2026. Despite trimming projected sales for OLC and increasing OpEx assumptions, maintaining a Buy rating for UNCY is recommended due to the company's strong potential in addressing unmet medical needs in the kidney disease market and its plan to raise additional equity later in the year.
Bears say
Unicycive Therapeutics is facing multiple risks, including potential delays and challenges in bringing its products to market, obtaining reimbursement for its products, and successfully executing its commercial operations. Despite having a strong cash balance and commitments for additional capital, the company's current shareholders may face significant dilution due to the conversion of warrants. In addition, Unicycive is not expected to be profitable until 2027 and may need to raise additional capital, which could further dilute current investors. These risks, along with a lower DCF-derived price target of $40, contribute to our negative outlook on the stock.
This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Unicycive Therapeutics (UNCY) Analyst Forecast & Price Prediction
Start investing in Unicycive Therapeutics (UNCY)
Order type
Buy in
Order amount
Est. shares
0 shares